menu
    • menu
    [{"orgOrder":0,"company":"Invex Therapeutics","sponsor":"Premier Research Group | University Hospital Birmingham | University of Iowa","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Invex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Invex Therapeutics \/ Premier Research Group | University Hospital Birmingham | University of Iowa","highestDevelopmentStatusID":"10","companyTruncated":"Invex Therapeutics \/ Premier Research Group | University Hospital Birmingham | University of Iowa"}]

    Find Clinical Drug Pipeline Developments & Deals by Invex Therapeutics

    Menu

    Invex Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Invex Therapeutics

                            Australia arrow
                            AusBiotech
                            Not Confirmed

                            Invex Therapeutics

                            Australia arrow
                            AusBiotech
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exenatide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Premier Research Group | University Hospital Birmingham | University of Iowa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Determine the Efficacy and Safety of Presendin in IIH

                            Details : Presendin (Exenatide) is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pseudotumor Cerebri.

                            Product Name : Presendin

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 26, 2022

                            Lead Product(s) : Exenatide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Premier Research Group | University Hospital Birmingham | University of Iowa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth